For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
0
views
0
references
 Top references
cited by
14
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Determine whether using CYP2C19 genotype to optimize antiplatelet therapy selection is cost effective over the initial 30 days and 1-year following percutaneous coronary intervention.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Pharmacogenomics
          Title: Pharmacogenomics
          Publisher: Future Medicine Ltd
          ISSN (Electronic): 1744-8042
          ISSN (Print): 1462-2416
          Publication date (Electronic): Aug 2017
          Volume: 18
          Issue: 12
          Affiliations
          [1 ] Division of Pharmaceutical Outcomes & Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
          [2 ] Division of Pharmacotherapy & Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
          [3 ] UNC Center for Pharmacogenomics & Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
          [4 ] UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
          [5 ] Division of Cardiology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
          Article
          DOI: 10.2217/pgs-2017-0075
          PubMed ID: 28745582
          SO-VID: 9ab7e984-6b8b-4974-8bf7-24632e4a0369
          History

          Keywords: readmission,prasugrel,genotype,pharmacogenomics,CYP2C19,cost–effectiveness,clopidogrel
          Data availability:
          Keywords: readmission, prasugrel, genotype, pharmacogenomics, CYP2C19, cost–effectiveness, clopidogrel

          Comments

          Comment on this article